Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Pyxis Oncology (NASDAQ: PYXS), a clinical-stage company focused on developing next-generation ADC therapeutics for difficult-to-treat cancers, has announced its participation in two upcoming investor conferences. The company's President, CEO, and CMO, Dr. Lara S. Sullivan, will engage in fireside chats at:

- The 2025 RBC Capital Markets Global Healthcare Conference in New York on May 21 at 2:05 p.m. ET

- The Jefferies Global Healthcare Conference in New York on June 5 at 4:55 p.m. ET

Investors can access live webcasts and replays of both presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website.

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences.

• 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ET
  
  
• Jefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET
  
  

A live webcast and replay of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.

Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com

FAQ

What investor conferences will Pyxis Oncology (PYXS) attend in May and June 2025?

Pyxis Oncology will participate in the RBC Capital Markets Global Healthcare Conference on May 21, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025, both in New York.

Who will represent Pyxis Oncology (PYXS) at the 2025 investor conferences?

Dr. Lara S. Sullivan, who serves as President, Chief Executive Officer, and Chief Medical Officer of Pyxis Oncology, will represent the company at both conferences.

How can investors access Pyxis Oncology's (PYXS) conference presentations?

Investors can access live webcasts and replays of the fireside chats through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.

What type of therapeutics is Pyxis Oncology (PYXS) developing?

Pyxis Oncology is developing next-generation ADC (Antibody-Drug Conjugate) therapeutics for difficult-to-treat cancers as a clinical-stage company.